Research To Practice | Oncology Videos

View Top 200 Chart

Back to Rankings Page

Science
**Research To Practice | Oncology Videos**

Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.

Latest Episodes:

Hodgkin Lymphoma | Oncology Today with Dr Neil Love: Current and Future Management of Hodgkin Lymphoma Sep 15, 2022

Show notes

Featuring perspectives from Dr Stephen Ansell, including the following topics:

Evolution of first-line management of advanced Hodgkin lymphoma (HL) (0:00)
Transplant strategies and outcomes for patients with relapsed/refractory HL (4:20)
Chemoimmunotherapy options for patients with HL (8:06)
Current and future management of limited-stage disease (11:52)
Addition of antibody-drug conjugates to HL treatment strategies (22:52)
Long-term management of HL (29:16)
Future management of HL — novel agents and strategies (34:56)

CME information and select publications

Interstitial Lung Disease | Oncology Today with Dr Neil Love: Interstitial Lung Disease in Patients Receiving Anticancer Therapy (Companion Faculty Lecture) Sep 13, 2022

Show notes

Featuring a slide presentation and related discussion from Dr Charles Powell, including the following topics:

Pathophysiology and clinical features of interstitial lung disease (ILD) associated with anticancer therapies (0:00)
Anticancer therapies linked to the development of ILD (5:28)
Patterns of ILD presentation and optimal evaluation of suspected ILD; treatment guidelines based on grade of severity (12:21)
ILD associated with antibody-drug conjugates (21:06)
Answers to common questions about the diagnosis and management of ILD in cancer patients (38:33)
Representative cases of ILD associated with anticancer drugs (43:21)

CME information and select publications

Interstitial Lung Disease | Oncology Today with Dr Neil Love: Interstitial Lung Disease in Patients Receiving Anticancer Therapy Sep 13, 2022

Show notes

Featuring an interview with Dr Charles Powell, including the following topics:

Role of the pulmonologist in the cancer care team; frequency of fatal and Grade 4 interstitial lung disease (ILD) with antibody-drug conjugates (0:00)
Pathophysiology of pneumonitis associated with checkpoint inhibitors versus antibody-drug conjugates; differences in presentation of ILD based on the cause of disease (8:04)
Myths and misperceptions about drug-related pneumonitis among general medical oncologists (14:08)
Monitoring for the onset of ILD using remote technology; typical time to onset of ILD (21:45)
Risk factors for the development of ILD among patients receiving anticancer therapy (25:58)
Incidence of ILD with bispecific antibodies; mechanisms underlying differences in the incidence of ILD associated with various antibody-drug conjugates (33:45)

CME information and select publications

Small Cell Lung Cancer | Meet The Professor: Optimizing the Management of Small Cell Lung Cancer — Part 1 Sep 09, 2022

Show notes

Featuring perspectives from Dr Jacob Sands, including the following topics:

Introduction: Journal Club (0:00)
Case: A woman in her mid 50s with extensive-stage small cell lung cancer (ES-SCLC) who had an excellent response to chemotherapy with immunotherapy (IO) and has been on maintenance IO for 2 years — Adam R Miller, MD (22:05)
Case: A woman in her mid 60s with ES-SCLC who presented with superior vena cava syndrome and has a near complete remission with chemo-IO — Namrata I Peswani, MD (28:27)
Case: A woman in her late 80s with metastatic SCLC possibly of adrenal origin who has an excellent response to chemo-IO — John Yang, MD (34:14)
Case: A woman in her mid 70s with recurrent ES-SCLC who has prolonged disease control on topotecan/trilaciclib — Ferdy Santiago, MD (41:09)
Case: A woman in her late 50s with ES-SCLC and brain metastases who responds to chemo-IO but later experiences disease progression (PD) and has toxicity with topotecan — Dr Miller (45:34)
Case: A woman in her late 60s with ES-SCLC who has PD on chemo-IO but responds to lurbinectedin with only mild toxicity — Mohamed K Mohamed, MD, PhD (48:28)
Case: A man in his early 70s with synchronous Stage III SCLC and Stage I non-small cell lung cancer who receives concurrent chemoradiation therapy — Daniel R Carrizosa, MD, MS (1:00:34)

CME information and select publications

Endometrial Cancer | Oncology Today with Dr Neil Love: Endometrial Cancer Edition Sep 08, 2022

Show notes

Featuring an interview with Dr Mansoor Raza Mirza, including the following topics:

Delivery of care models for endometrial cancer (0:00)
Molecular profiling and treatment for endometrial cancer (1:57)
Current use of immunotherapy for the management of endometrial cancer (8:56)
Mitigating and managing immunotherapy-associated adverse events for patients with endometrial cancer (13:40)
Immune checkpoint inhibitors for localized endometrial cancer(18:51)
Practical considerations in the care of patients with endometrial cancer (22:17)
Targeted therapy for patients with endometrial cancer (30:08)

CME information and select publications

Endometrial Cancer | Oncology Today with Dr Neil Love: Endometrial Cancer Edition (Companion Faculty Lecture) Sep 08, 2022

Show notes

Featuring a slide presentation and related discussion from Dr Mansoor Raza Mirza, including the following topics:

Molecular classification of endometrial cancer and immunotherapy options for patients with microsatellite instabiliity-high/DNA mismatch repair deficient endometrial cancer (0:00)
Immunotherapy for mismatch repair-proficient endometrial cancer (9:18)
Ongoing Phase III trials evaluating immunotherapy for endometrial cancer (18:11)

CME information and select publications

Gastroesophageal Cancers | Meet The Professor: Optimizing the Management of Gastroesophageal Cancers — Part 5 Sep 07, 2022

Show notes

Featuring perspectives from Dr John Strickler, including the following topics:

Introduction (0:00)
Case: A man in his early 60s with gastroesophageal junction (GEJ) adenocarcinoma who responds to neoadjuvant chemoradiation therapy but declines surgery and develops progressive disease (HER2 1+, PD-L1 2%) — Minesh Dinubhai Patel, MD (13:54)
Case: A frail woman in her late 80s with unresectable gastric cancer who chooses to receive systemic therapy (PD-L1 0%, HER2 negative, MSS) — Matthew R Strickland, MD (18:20)
Case: A man in his mid 60s with T3N1M mixed gastric adenocarcinoma who responds well to neoadjuvant FLOT and has minimal residual disease at surgery — Ranju Gupta, MD (23:01)
Case: A man in his early 60s with a history of prostate cancer who is now diagnosed with T2N1M0, HER2-positive GEJ adenocarcinoma — Dr Strickland (29:23)
Case: A man in his early 30s with metastatic HER2-positive gastric adenocarcinoma who is responding well to FOLFOX, trastuzumab and nivolumab — Priya Rudolph, MD, PhD (33:00)
Case: A man in his early 60s with metastatic HER2-positive esophageal cancer and a germline CHEK2 mutation who experiences disease progression on chemotherapy, pembrolizumab, trastuzumab and later T-DXd (PD-L1 12%) — Warren S Brenner, MD (46:34)
Case: A man in his mid 70s with symptomatic anemia who is diagnosed with metastatic esophageal adenocarcinoma (PD-L1 8%, MSS, HER2 1+) — Dr Strickland (55:44)
Case: A woman in her early 60s with squamous cell esophageal carcinoma metastatic to bone (PD-L1 TPS 10%) — Dr Strickland (58:46)

CME information and select publications

Oncology Today with Dr Neil Love: Ocular Toxicities in Patients Receiving Anticancer Therapy (Companion Faculty Lecture) Sep 06, 2022

Show notes

Featuring a slide presentation and related discussion from Dr Asim Farooq, including the following topics:

Molecular classification of endometrial cancer and immunotherapy options for patients with microsatellite instabiliity-high/DNA mismatch repair deficient endometrial cancer (0:00)
Immunotherapy for mismatch repair-proficient endometrial cancer (9:18)
Ongoing Phase III trials evaluating immunotherapy for endometrial cancer (18:11)

CME information and select publications

Ocular Toxicities | Oncology Today with Dr Neil Love: Ocular Toxicities in Patients Receiving Anticancer Therapy Sep 06, 2022

Show notes

Featuring an interview with Dr Asim Farooq, including the following topics:

Educating patients about ocular toxicities associated with anticancer therapies (0:00)
Differentiating therapy-related ocular toxicities from symptoms not associated with anticancer drugs (3:44)
Optimal prevention of ocular toxicities from antibody-drug conjugates; symptoms and management of central serous retinopathy (9:36)
Pathophysiology of ocular symptoms associated with ALK inhibitors and BRAF/MEK inhibitors (16:40)
Myths and misperceptions among physicians about ophthalmic toxicities (22:29)

CME information and select publications

Non-Small Cell Lung Cancer | Meet The Professor: Non-Small Cell Lung Cancer with an Actionable Target Beyond EGFR — Part 4 Sep 02, 2022

Show notes

Featuring perspectives from Dr Stephen Liu, including the following topics:

Introduction: Journal Club with Stephen V Liu, MD (0:00)
Case: A woman in her mid 40s with metastatic lung adenocarcinoma with a ROS1 fusion — Minesh Dinubhai Patel, MD (10:54)
Case: A woman in her late 70s with metastatic lung adenocarcinoma with a HER2 mutation — Adam R Miller, MD (17:40)
Case: A woman in her early 60s with RET-fusion-driven lung adenocarcinoma — Kapisthalam (KS) Kumar, MD (22:30)
Case: A woman in her early 70s with metastatic adenocarcinoma of the lung with a MET exon 14 mutation — Dr Kumar (31:02)
Case: A woman in her early 70s with recurrent lung adenocarcinoma with a MET T263M mutation — Priya Rudolph, MD, PhD (34:15)
Case: A woman in her late 70s with metastatic adenocarcinoma with a MET exon 14 mutation — Gigi Chen, MD (39:53)
Case: A woman in her late 70s with ALK fusion-driven lung adenocarcinoma — Rajni Sinha, MD, MRCP (45:52)
Case: A woman in her late 60s with metastatic lung adenocarcinoma and a KRAS G12C mutation — Dr Miller (52:08)
Case: A woman in her early 60s with metastatic lung adenocarcinoma and an NRG1 fusion — Jiaxin (Jason) Niu, MD, PhD (57:06)

CME information and select publications

Our TOPPODCAST Picks

Follow Us

Stay Connected

Research To Practice | Oncology Videos

Related Podcasts

Links

Stay Connected